Copper silicate nanoparticle-mediated delivery of astragaloside-IV for osteoarthritis treatment by remodeling the articular cartilage microenvironment.

With the increasing global aging population, osteoarthritis (OA) has emerged as a major public health concern. OA pathogenesis is characterized by a complex interplay among inflammatory cytokines, reactive oxygen species, and extracellular matrix components, leading to cartilage degradation. Astragaloside-IV (AS-IV), a natural antioxidant, has shown promise in alleviating OA symptoms but is limited by poor bioavailability and ineffective cartilage drug delivery.

Astaxanthin Prevents Glucocorticoid-Induced Femoral Head Osteonecrosis by Targeting Ferroptosis through the JAK2/STAT3 Signaling Pathway.

Glucocorticoid (GC) is extensively used in clinical practice, and the osteonecrosis of the femoral head caused by them is a common issue in orthopedic surgery, yet the underlying mechanisms remain unclear. Astaxanthin (AST), a potent natural antioxidant, has an unexplored impact on GC-induced osteonecrosis of the femoral head (GIONFH). This study explores the effects and mechanisms of AST in counteracting dexamethasone (Dex)-induced ferroptosis and GIONFH.